[Assessment of efficacy of Diane-35 in androgenetic feminine alopecia].
The aim of the study was to carry out clinical and trichological examination (trichogram and assessment of hair loss) before and after therapy in 25 women aged 31-35 years with androgenetic alopecia. Diane-35 was given over 6-9 months once a day in a dose of 1 coated tablet beginning the therapy on the first day of menstrual cycle. After the administration of a whole package (1 blister) the drug was paused for 7 days which resulted in the occurrence of menorrhoea. The study showed that Diane-35 used for 6-9 months decreases clearly the loss of hair, hair thinning and seborrhoea.
Brzezińska-Wcisło
Ligia
L
Katedry i Kliniki Dermatologii Slaskiej Akademii Medycznej w Katowicach.
D000328:Adult; D000505:Alopecia / Q000175:diagnosis / Q000188:drug therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006197:Hair / Q000187:drug effects*; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome
D000726:Androgen Antagonists; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination